Home » Stocks » HOLX

Hologic, Inc. (HOLX)

Stock Price: $68.39 USD -1.12 (-1.61%)
Updated November 30, 11:22 AM EST - Market open

Stock Price Chart

Key Info

Market Cap 17.58B
Revenue (ttm) 3.78B
Net Income (ttm) 1.12B
Shares Out 257.01M
EPS (ttm) 4.21
PE Ratio 16.24
Forward PE 20.04
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 30
Last Price $68.39
Previous Close $69.51
Change ($) -1.12
Change (%) -1.61%
Day's Open 69.52
Day's Range 68.12 - 69.87
Day's Volume 352,842
52-Week Range 29.38 - 76.67

More Stats

Market Cap 17.58B
Enterprise Value 19.93B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 257.01M
Float n/a
EPS (basic) 4.24
EPS (diluted) 4.21
FCF / Share 2.82
Dividend n/a
Dividend Yield n/a
Earnings Yield 6.16%
FCF Yield 4.21%
Payout Ratio n/a
Shares Short 5.22M
Short Ratio 2.41
Short % of Float n/a
Beta 1.40
PE Ratio 16.24
Forward PE 20.04
P/FCF Ratio 23.75
PS Ratio 4.65
PB Ratio 6.60
Revenue 3.78B
Operating Income 1.11B
Net Income 1.12B
Free Cash Flow 740.20M
Net Cash -2.36B
Net Cash / Share -9.17
Gross Margin 66.55%
Operating Margin 29.26%
Profit Margin 29.50%
FCF Margin 19.60%
ROA 10.61%
ROE 46.05%
ROIC 26.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (16)

Buy 10
Overweight 1
Hold 5
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$86.33*
(26.23% upside)
Low
80.0
Current: $68.39
High
103.0
Target: 86.33
*Average 12-month price target from 12 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2020201920182017201620152014201320122011
Revenue3,7763,3673,2183,0592,8332,7052,5312,4922,0031,789
Revenue Growth12.15%4.64%5.2%7.98%4.72%6.89%1.54%24.45%11.92%-
Gross Profit2,2281,1711,6971,6211,5631,4331,2461,161994923
Operating Income1,105-124-238471549455280-895152366
Net Income1,115-204-11175633113217.30-1,173-73.60157
Shares Outstanding263269275280280281275269264261
Earnings Per Share4.21-0.76-0.402.641.160.450.06-4.36-0.280.59
EPS Growth---127.59%157.78%650%----
Operating Cash Flow8976507338.30798797508494370456
Capital Expenditures-156-114-106-108-94.50-89.40-80.20-90.10-78.70-55.66
Free Cash Flow740536627-99.30704707428404292400
Cash & Equivalents701602667541548493742829566713
Total Debt3,0583,0763,3273,3473,3453,6124,2684,8065,0361,489
Net Cash / Debt-2,357-2,474-2,660-2,807-2,797-3,120-3,526-3,977-4,469-776
Assets7,1966,4427,2317,9807,3177,6438,4159,00110,4776,009
Liabilities4,4894,3264,8025,1955,1745,5636,3527,0597,5163,072
Book Value2,7052,1162,4292,7852,1432,0792,0631,9422,9612,937
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Hologic, Inc.
Country United States
Employees 5,814
CEO Stephen P. MacMillan

Stock Information

Ticker Symbol HOLX
Stock Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Unique Identifier NASDAQ: HOLX
IPO Date June 21, 1990

Description

Hologic develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima quantitative viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. It has a collaboration with RadNet, Inc. to advance the use of artificial intelligence in breast health. Hologic, Inc. was founded in 1985 and is headquartered in Marlborough, Massachusetts.